{
    "clinical_study": {
        "@rank": "124452", 
        "arm_group": [
            {
                "arm_group_label": "single arm (phase I)", 
                "arm_group_type": "Experimental", 
                "description": "dose escalation"
            }, 
            {
                "arm_group_label": "volasertib + decitabine (phase II)", 
                "arm_group_type": "Experimental", 
                "description": "open label, combination"
            }, 
            {
                "arm_group_label": "decitabine (phase II)", 
                "arm_group_type": "Active Comparator", 
                "description": "open label, comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to investigate the maximum tolerated dose (MTD), safety and\n      efficacy of volasertib in combination with decitabine in patients with acute myeloid\n      leukaemia (AML)"
        }, 
        "brief_title": "Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Leukemia, Myeloid, Acute", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Phase I part:  Male or female elderly patients >=60 years old with previously\n             untreated or relapsed/refractory AML after one prior chemotherapy\n\n          2. Phase IIa part:  Male or female elderly patients >=60 years old with previously\n             untreated AML\n\n          3. Histologically or cytologically confirmed AML.\n\n          4. Patient is eligible for decitabine treatment\n\n          5. Eastern co-operative oncology group (ECOG) performance score <=2 at screening\n\n          6. Signed and dated written informed consent\n\n        Exclusion criteria:\n\n          1. Phase IIa: prior chemotherapy for AML\n\n          2. Acute promyelocytic leukemia (FAB subtype M3)\n\n          3. Second malignancy currently requiring active therapy\n\n          4. Current clinical central nervous system (CNS) symptoms deemed by the investigator to\n             be related to leukemic CNS involvement\n\n          5. QTcF prolongation deemed clinically relevant by the investigator (e.g., QTcF > 470\n             ms, congenital long QT syndrome, etc.).\n\n          6. Concomitant anti-leukemic treatment\n\n          7. Concomitant anti-infective therapy which, in the opinion of the investigator, is\n             considered relevant for the evaluation of the efficacy or safety of the trial drug\n\n          8. Patients with a systemic fungal, bacterial, viral, or other infection not controlled\n\n          9. Contraindications for decitabine treatment\n\n         10. Treatment with any investigational drug within 2 weeks of administration of first\n             study medication dose or within less than five half times of the investigational drug\n             before treatment with the present trial drug and / or persistence of toxicities of\n             prior anti-leukemic therapies\n\n         11. Prior treatment with a Plk1 inhibitor such as volasertib  or treatment in a clinical\n             trial using a Plk inhibitory compound"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003573", 
            "org_study_id": "1230.30", 
            "secondary_id": "2013-001752-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "single arm (phase I)", 
                "description": "decitabine iv fixed dose", 
                "intervention_name": "decitabine iv", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "volasertib + decitabine (phase II)", 
                "description": "volasertib iv infusion RP2D", 
                "intervention_name": "volasertib iv infusion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "single arm (phase I)", 
                "description": "volasertib iv infusion RP2D", 
                "intervention_name": "volasertib iv infusion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "volasertib + decitabine (phase II)", 
                "description": "decitabine iv fixed dose", 
                "intervention_name": "decitabine iv", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "decitabine (phase II)", 
                "description": "decitabine iv fixed dose", 
                "intervention_name": "decitabine iv", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Decitabine", 
                "Azacitidine"
            ]
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "1230.30.10002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "1230.30.10004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "1230.30.10005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "1230.30.10003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1230.30.10001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidents of DLTs for volasertib in combination with decitabine", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Complete Remission (CR)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Complete Remission with incomplete blood count recovery (CRi)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003573"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Event Free Survival (EFS)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "relapsed free survival", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}